Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities

3 Months Ended

Mar. 31, 2016

9. Accrued Expenses and Other Long-Term Liabilities

Accrued expenses and other long-term liabilities consisted of the following:

	March 31,		December 31,
($ in thousands)	2016		2015
Accrued expenses:
Professional fees	$	749	$	382
Salaries, bonuses and related benefits		762		2,492
Ovamed manufacturing rights - short term component		1,500		1,500
Research and development		746		810
Dr. Falk Pharma milestone		2,828		2,717
COH upfront fee for sponsored research for PepVax (see Note 6)		1,007		-
Accrued lease costs for abandoned properties		146		146
Other		521		523
Total accrued expenses	$	8,259	$	8,570

Other long-term liabilities:
Long-term accrued lease costs for abandoned properties		17		91
Deferred rent		2,399		493
Total other long-term liabilities	$	2,416	$	584